Date	e: <u>Dec. 15th, 2023</u>		
You	r Name: <u>Takako Ikegar</u>	ni	
Mar	nuscript Title: Narrative revi	ew of malignant ascites: I	Epidemiology, pathophysiology, assessment, and treatment
	nuscript number (if known):		
	, , , ,		
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to th	• •	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	institution
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present	XNone	
_	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V None	
3	Royalties or licenses	XNone	

Consulting fees

_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
	Double in the control of the control	V None	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the follo	owing box:
N	lone.		

	e: <u>Dec. 15th, 2023</u>			
You	r Name: <u>Hiroto Ishiki</u>			
Mar	nuscript Title: Narrative revi	iew of malignant ascites: I	Epidemiology, pathophysiology, assessment, and treatmen	ıt
	nuscript number (if known):			_
	,			
rela part to ti	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the second se	
	following questions apply t	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to tl	• •	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items	,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	institution	
		needed)		
		•	al planning of the work	
	-	Time frame: Since the initi	al planning of the work	
1	All support for the present	•	al planning of the work	
1	manuscript (e.g., funding,	Time frame: Since the initi	al planning of the work	
1	manuscript (e.g., funding, provision of study materials,	Time frame: Since the initi	al planning of the work	
1	manuscript (e.g., funding, provision of study materials, medical writing, article	Time frame: Since the initi	al planning of the work	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Time frame: Since the initi	al planning of the work	
1	manuscript (e.g., funding, provision of study materials, medical writing, article	Time frame: Since the initi	al planning of the work	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Time frame: Since the initi	al planning of the work	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Time frame: Since the initi	al planning of the work	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Time frame: Since the initi		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initiXNone		
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Time frame: Since the initi		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initiXNone		

Royalties or licenses

Consulting fees

_X__None

X__None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
	Double in the control of the control	V None	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the follo	owing box:
N	lone.		

	e: <u>Dec. 16th, 2023</u>					
Your Name: Toru Kadono						
Mar	Manuscript Title: <u>Narrative review of malignant ascites</u> : <u>Epidemiology</u> , <u>pathophysiology</u> , <u>assessment</u> , <u>and treatment</u>					
Mar	nuscript number (if known):	Unkown				
	•	-	relationships/activities/interests listed below that are			
	parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment					
	•	-	f you are in doubt about whether to list a			
rela	tionship/activity/interest, it	t is preferable that you do s	50.			
	following questions apply to suscript only.	o the author's relationship	s/activities/interests as they relate to the current			
to th		nsion, you should declare a	efined broadly. For example, if your manuscript pertains II relationships with manufacturers of antihypertensive manuscript.			
	em #1 below, report all sup time frame for disclosure is	·	in this manuscript without time limit. For all other items,			
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate				
		-	institution)			
		none (add rows as				
		needed)				
		Time frame: Since the initial	planning of the work			
1	All support for the present	XNone				
	manuscript (e.g., funding, provision of study materials,					
	medical writing, article					
	processing charges, etc.) No time limit for this item.					
	140 time mint for tims item.					
		Time frame: past	36 months			
2	Grants or contracts from	XNone				
	any entity (if not indicated					
2	in item #1 above).	V Nava				
3	Royalties or licenses	X None				

Consulting fees

_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
	Double in the control of the control	V None	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the follo	owing box:
N	lone.		

Date	e: <u>Dec. 15th, 2023</u>		
You	r Name: <u>Tetsuya Ito</u>		
Mar	nuscript Title: Narrative revi	ew of malignant ascites: I	Epidemiology, pathophysiology, assessment, and treatment
	nuscript number (if known):		
		-	relationships/activities/interests listed below that are
part to ti	ies whose interests may be	affected by the content o	f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the current
to tl	• •	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	X None	
-	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
	Double in the control of the control	V None	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the follo	owing box:
N	lone.		

Date	e: <u>Dec. 17th, 2023</u>		
You	r Name: <u>Naosuke Yoko</u>	omichi	
Mar	nuscript Title: <u>Narrative revi</u>	ew of malignant ascites: E	pidemiology, pathophysiology, assessment, and treatment
Mar	nuscript number (if known):	Unkown	
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to tl med In it	ne epidemiology of hypertentication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
1	in item #1 above).	V. Nana	
3	Royalties or licenses	XNone	

Consulting fees

X__None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
	Double in the control of the control	V None	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the follo	owing box:
N	lone.		